Entities / Company
Janssen Biotech.
Biotechnology company
- Reports this week
- 1
- Active events
- 2
- Connections
- 9
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Protagonist Therapeutics co-discovered ICOTYDE with Johnson & Johnson and subsequently licensed the technology to Janssen Biotech.Well supported7 reports1 development inside
-
J&J and Janssen Biotech jointly won summary judgment in a Virginia court regarding J&J's acquisition, with FTC filing an amicus brief.Some support1 report
Earlier this month
One to three months ago
No events began in the chosen period. Widen it, or reset.
Around Janssen Biotech this week
News at the entities that move Janssen Biotech most-
Johnson & Johnson StructuralP&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Moves Janssen Biotech
-
company StructuralBoard approved a quarterly cash dividend increase on August 1, 2026.Moves Janssen Biotech
Connections
The 4 strongest of 9, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Johnson & Johnson Structural
Janssen Biotech operates as a licensed entity under Johnson & Johnson.
-
Protagonist Therapeutics (United States) Transactional
Protagonist Therapeutics licensed the drug Icotrokinra to Janssen Biotech following joint discovery and collaboration.
-
company Structural
Entity B supplies and licenses the product ICOTYDE to Janssen Biotech (Entity A).
-
Legend Biotech Operational
Legend Biotech and Janssen Biotech are partnering to advance cell therapy treatments.